Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs TG Therapeutics Inc — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $26.12 (market cap $159.33M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 51.2× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 54 Days and TG Therapeutics Inc for 16 Days on average.
| RDTE | TGTX | |
|---|---|---|
Market Cap | $159.33M | $8.16B |
Volume | 248,058 | 1,735,121 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $59.06 |
52-Week Low | $25.96 | $26.94 |
Typical Hold Time | 54 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDTE trades at $26.12, showing minimal daily movement with a slight decline of 0.08%. The technical outlook is bearish, driven by negative moving average signals, while oscillators are neutral. The ETF has a history of frequent, small dividend payments, but key valuation and profitability ratios are unavailable. Recent news highlights concerns about capital erosion risk in covered-call strategies compared to peers.
The outlook for RDTE is cautious due to bearish technicals and media skepticism about its income strategy's sustainability. Investment appeal hinges on high yield, but risks include capital depreciation and underperformance versus benchmarks. Investors should weigh income generation against potential long-term value erosion in a competitive ETF landscape.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
